Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akihito Matsuoka

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
International Journal of Environmental Research and Public Health|August 27, 2021
Association between Big Five Personality Traits and Participation in Cardiac Rehabilitation in Japanese Patients with Cardiovascular Disease: A Retrospective Cohort StudyTakuji Adachi, Yuki Tsunekawa, Akihito Matsuoka, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|September 27, 2025
Recurrent pneumococcal OPSI after splenectomy: The need for optimized vaccination and prophylaxisMasashi Nishiyama, Kyoko Yokota, Akihito Matsuoka, et al.
International Journal of Hematology|March 11, 2022
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidineAkihito Matsuoka, Masaki Tanibuchi, Ieharu Yamazaki, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 14, 2012
[Effective treatment with rituximab for primary thrombotic thrombocytopenic purpura complicated with multiple cerebral infarctions]Yukiko Hamasaki, Akihito Matsuoka, Masato Waki, et al.
European Journal of Cardiovascular Nursing|May 10, 2022
Association between Rapid Dementia Screening Test score and clinical events in elderly patients with cardiovascular disease: a retrospective cohort studyTakuji Adachi, Yuki Tsunekawa, Akihito Matsuoka, et al.
Current Pharmaceutical Design|May 11, 2012
Approach to new therapeutics: investigation by the use of MDS-derived cell linesTakayuki Tsujioka, Akihito Matsuoka, Yumi Tohyama, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 18, 2023
[Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia]Kodai Kunisada, Akihito Matsuoka, Syunsuke Yoshida, et al.
Journal of Geriatric Cardiology : JGC|May 17, 2021
Usefulness of the Japanese version of Rapid Dementia Screening Test for mild cognitive impairment in older patients with cardiovascular disease: a cross-sectional studyTakuji Adachi, Yuki Tsunekawa, Akihito Matsuoka, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 14, 2010
[Multiple autologous transplantations with intermediate-dose melphalan for two elderly patients with relapsed or refractory diffuse large B-cell lymphoma]Tetsuo Nishimoto, Kazuo Hatanaka, Akihito Matsuoka, et al.
International Journal of Hematology|September 6, 2018
KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell lineHiroyuki Morita, Akihito Matsuoka, Jun-Ichiro Kida, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
International Journal of Environmental Research and Public Health|August 27, 2021
Association between Big Five Personality Traits and Participation in Cardiac Rehabilitation in Japanese Patients with Cardiovascular Disease: A Retrospective Cohort StudyTakuji Adachi, Yuki Tsunekawa, Akihito Matsuoka, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|September 27, 2025
Recurrent pneumococcal OPSI after splenectomy: The need for optimized vaccination and prophylaxisMasashi Nishiyama, Kyoko Yokota, Akihito Matsuoka, et al.
International Journal of Hematology|March 11, 2022
Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidineAkihito Matsuoka, Masaki Tanibuchi, Ieharu Yamazaki, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 14, 2012
[Effective treatment with rituximab for primary thrombotic thrombocytopenic purpura complicated with multiple cerebral infarctions]Yukiko Hamasaki, Akihito Matsuoka, Masato Waki, et al.
European Journal of Cardiovascular Nursing|May 10, 2022
Association between Rapid Dementia Screening Test score and clinical events in elderly patients with cardiovascular disease: a retrospective cohort studyTakuji Adachi, Yuki Tsunekawa, Akihito Matsuoka, et al.
Current Pharmaceutical Design|May 11, 2012
Approach to new therapeutics: investigation by the use of MDS-derived cell linesTakayuki Tsujioka, Akihito Matsuoka, Yumi Tohyama, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 18, 2023
[Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia]Kodai Kunisada, Akihito Matsuoka, Syunsuke Yoshida, et al.
Journal of Geriatric Cardiology : JGC|May 17, 2021
Usefulness of the Japanese version of Rapid Dementia Screening Test for mild cognitive impairment in older patients with cardiovascular disease: a cross-sectional studyTakuji Adachi, Yuki Tsunekawa, Akihito Matsuoka, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 14, 2010
[Multiple autologous transplantations with intermediate-dose melphalan for two elderly patients with relapsed or refractory diffuse large B-cell lymphoma]Tetsuo Nishimoto, Kazuo Hatanaka, Akihito Matsuoka, et al.
International Journal of Hematology|September 6, 2018
KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell lineHiroyuki Morita, Akihito Matsuoka, Jun-Ichiro Kida, et al.
Pageof 2